Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

NCT04854499 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04854499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04854499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
September 7, 2021
Completion date
October 2, 2024
Enrollment
193 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma